Therapeutic area intelligence for Lung Adenocarcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Bruceine →

Recent signals(1)

CompetitiveJuly 24, 2026

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

Bruceine D epigenetically restores SMAD3 expression and suppresses malignant progression in EGFR-TKI-resistant lung adenocarcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Lung Adenocarcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.